Results 11 to 20 of about 35,474 (226)

A Case Report on Disseminated <i>Mycobacterium avium</i> Complex Infection in an Otherwise Healthy Individual-A Diagnostic Challenge. [PDF]

open access: yesClin Case Rep
ABSTRACT Disseminated Mycobacterium avium complex (MAC) infection can mimic tuberculosis (TB) in immunocompetent individuals, leading to diagnostic and therapeutic challenges. Clinicians should consider nontuberculous mycobacteria (NTM) in patients unresponsive to anti‐tubercular therapy (ATT), especially in endemic regions.
Hridoy AB   +7 more
europepmc   +2 more sources

Differential Protein Expression in Exponential and Stationary Growth Phases of Mycobacterium avium subsp. hominissuis 104

open access: yesMolecules, 2021
Mycobacterium avium complex (MAC) is the most common non-tuberculous mycobacterium (NTM) and causes different types of pulmonary diseases. While genomic and transcriptomic analysis of Mycobacterium avium 104 (M.
Shymaa Enany   +2 more
doaj   +1 more source

Protection efficacy of Argentinian isolates of Mycobacterium avium subsp. paratuberculosis with different genotypes and virulence in a murine model [PDF]

open access: yes, 2018
Paratuberculosis is a chronic disease caused by Mycobacterium avium subsp. paratuberculosis (Map). The disease causes economic losses and, therefore, it is imperative to follow proper control strategies, which should include an effective vaccine. Several
Alvarado Pinedo, María Fiorella   +8 more
core   +1 more source

A young boy with disseminated Mycobacterium avium complex infection

open access: yesInternational Journal of Infectious Diseases, 2019
The case of a Chinese boy with no medical history, who presented with diarrhea and weight loss of 14-month duration and rashes and fever or 6-month duration, is described.
Kangkang Yu   +3 more
doaj   +1 more source

A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis. [PDF]

open access: yes, 2009
BACKGROUND: Antibiotic therapy targeting chronic mycobacterial disease is often ineffective due to problems with the emergence of drug resistance and non-replicating persistent intracellular antibiotic resistant phenotypes.
Bull, TJ   +3 more
core   +3 more sources

Genomic variations associated with attenuation in Mycobacterium avium subsp paratuberculosis vaccine strains [PDF]

open access: yes, 2013
BACKGROUND: Mycobacterium avium subspecies paratuberculosis (MAP) whole cell vaccines have been widely used tools in the control of Johne's disease in animals despite being unable to provide complete protection. Current vaccine strains derive from stocks
Bull, TJ   +7 more
core   +1 more source

Hypersensitivity Pneumonitis Associated with Environmental Mycobacteria [PDF]

open access: yes, 2005
A previously healthy man working as a machine operator in an automotive factory developed respiratory symptoms. Medical evaluation showed abnormal pulmonary function tests, a lung biopsy showed hypersensitivity pneumonitis, and his illness was traced to ...
Akshay Sood   +7 more
core   +2 more sources

Potential therapeutic effect of ninjinyoeito for the treatment of pulmonary nontuberculous mycobacterial infections: A case report

open access: yesJournal of Family Medicine and Primary Care, 2019
A 40-year-old man presented with refractory pulmonary Mycobacterium avium complex infection, despite administration of antituberculous drugs for 2 years.
Tatsuya Nogami
doaj   +1 more source

Risk factors for drug resistant tuberculosis in Leicestershire - poor adherence to treatment remains an important cause of resistance [PDF]

open access: yes, 2013
In the light of rising numbers of tuberculosis (TB) cases in the United Kingdom, the problem of anti-tubercular drug resistance remains a significant concern.
Hayward, AC   +3 more
core   +2 more sources

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera

open access: yesInternational Journal of Infectious Diseases, 2019
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal ...
Sylvain Lescuyer   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy